Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.73 |
| ▸ | APP | P05067 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene Core SCHEMBL2567321 | 0.85 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| Raloxifene Core SCHEMBL29941293 | 0.85 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL13086548 | 0.83 | ESR1 (0.58) | ESR1ESR2APPMAPTHDAC3 | |
| SCHEMBL3139631 | 0.82 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL17805782 | 0.80 | ESR1 (0.61) | ESR1ESR2APPMAPTSULT1A1 | |
| SCHEMBL3066503 | 0.79 | APP (0.59) | ESR1ESR2APPMAPTHDAC6 | |
| SCHEMBL204092 | 0.79 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL13071222 | 0.79 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL27451537 | 0.79 | APP (0.62) | ESR1ESR2APPMAPTHSD17B1 | |
| SCHEMBL19171602 | 0.79 | ESR1 (0.80) | ESR1ESR2APPSULT1A1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497260-B2 | 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient | Industry-University Cooperation Foundation Sogang University (KR) | 2013-07-30 | — | — | US | disclosed |
| US-8497260-B2 | 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient | Industry-University Cooperation Foundation Sogang University (KR) | 2013-07-30 | — | — | US | disclosed |
| US-8497260-B2 | 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient | Industry-University Cooperation Foundation Sogang University (KR) | 2013-07-30 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | Industry-University Cooperation Foundation Sogang University | 2010-10-14 | — | — | US | disclosed |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | Industry-University Cooperation Foundation Sogang University | 2010-10-14 | — | — | US | disclosed |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | Industry-University Cooperation Foundation Sogang University | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | ESR1 2563/4885ESR2 2656/4885APP 145/4885 |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | APP, PSEN1, PSEN2 | ESR1 3713/4885ESR2 1558/4885APP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.